Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Alkermes plc. executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of 2,034 Ordinary Shares on July 6, 2026 at $54.03 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, he directly holds 227,490 Ordinary Shares, so the transaction represents only a small fraction of his overall position.
Alkermes plc files a notice of proposed sale of Common Stock under Rule 144 by a selling holder. The excerpt lists proposed sales by David Gaffin of 70,315.38, 67,528.80 and 87,563.70 on 04/06/2026, 05/04/2026 and 06/04/2026, respectively.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported a combination of option exercise and share sales in Ordinary Shares. He exercised employee stock options for 5,000 shares at a conversion price of $19.34 per share and, on the same date, sold a total of 9,000 Ordinary Shares in open-market transactions at weighted average prices of $51.4613 and $52.1314. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the transactions, he directly holds 82,389 Ordinary Shares and 1,356 employee stock options.
Alkermes plc reported proposed dispositions of Ordinary Shares via Form 144 associated with insider transactions. The excerpt lists four monthly sales of 9,000 shares each on 03/02/2026, 04/01/2026, 05/01/2026, and 06/01/2026 with gross proceeds of $267,485.14, $319,604.00, $300,559.55, and $375,043.23, respectively. The filing also records a broker-assisted cashless exercise of 5,000 shares on 07/01/2026 and vesting of 4,000 shares as a performance award on 02/05/2026.
Alkermes plc reported that alixorexton, its investigational orexin 2 receptor agonist for sleep disorders, has received orphan drug designations in both the U.S. and Europe. The FDA granted orphan status for idiopathic hypersomnia, while the European Commission granted orphan status for narcolepsy.
Alixorexton is in phase 3 Brilliance studies for narcolepsy types 1 and 2 and in the phase 2 Vibrance-3 study for idiopathic hypersomnia. Orphan designation can provide tax credits, reduced regulatory fees and market exclusivity, supporting development of this potential treatment for rare, chronic neurological conditions.
Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at a price of $45.10 per share. After this transaction, he directly holds 25,680 Ordinary Shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Wright on March 11, 2026, indicating the trade was scheduled in advance rather than timed discretionarily.
Alkermes plc submitted a Rule 144 notice related to 2,000 shares of Common Stock tied to the vesting of restricted stock unit awards on 05/21/2026. The filing lists a shares outstanding figure of 166,675,807 as of 06/12/2026 as context.
Alkermes plc EVP and Chief Legal Officer David Joseph Gaffin reported an open-market sale of 2,034 Ordinary Shares of Alkermes on June 4, 2026 at an average price of $43.05 per share. After this transaction, he directly holds 229,524 Ordinary Shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on November 19, 2025, indicating it was scheduled in advance rather than timed opportunistically.
Alkermes plc submitted a Form 144 notice concerning proposed sales of Common Stock on 06/04/2026 for shares traded on NASDAQ. The filing lists vested restricted stock unit awards of 506 (03/03/2015) and 1,528 (03/01/2018) shares and records four prior sales in the past three months: 59,575.86, 60,531.84, 70,315.38, and 67,528.80.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 5,000 Ordinary Shares at $19.34 per share and sold 9,000 Ordinary Shares in an open-market transaction at a weighted average price of $41.6715 per share.
Both the option exercise and the share sale were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025, meaning they were pre-arranged. The sale price reflects multiple trades between $41.37 and $42.19. After these transactions, Hopkinson directly holds 77,389 Ordinary Shares.